SINGAPORE, Dec. 29, 2025 — EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or “the Company”), a Singapore-headquartered non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China, today announced its plans to launch EUDA Helixé 2.0 in January 2026—a next-generation upgrade of its premium youthful vitality and longevity supplement. EUDA Helixé 2.0 includes improvements in formulation potency, ingredient technology, delivery mechanisms, packaging design, and global market preparedness.
Strengthened Formula and Ingredient Optimization
EUDA Helixé 2.0 contains 20% more New Zealand-sourced deer placenta powder, with the dosage increased from 100 mg to 120 mg—strengthening the supplement’s standing as a high-potency vitality product. As part of the formulation update, L-glutathione has been swapped for D-alpha-tocopherol (1.4 mg of Vitamin E equivalent). This adjustment is intended to boost antioxidant stability, aid cellular protection, improve skin health, and enhance overall youthful vitality—aligning EUDA Helixé 2.0 with long-term wellness and anti-aging goals.
Advanced Encapsulation and Preservation Technology
EUDA Helixé 2.0 uses an improved ingredient preservation and delivery system designed to boost stability, absorption efficiency, and shelf life:
- Freeze Drying: Powder-based ingredients undergo freeze-drying to maintain nutrient potency while eliminating moisture without changing their molecular structure.
- Refining Technology: Oil-based ingredients are refined to enhance stability, lower allergenic and reactive potential, and improve resistance to heat and light.
- Nitrogen Encapsulation: Nitrogen shielding reduces oxidation and hydrolysis, prolonging the product’s shelf life.
- Nano Emulsification (Replacing Enteric Coating): The nano-sized formula enhances solubility, bioavailability, and absorption speed—enabling more efficient nutrient delivery than traditional enteric coating.
This nano-based delivery system allows EUDA Helixé 2.0 to have a smaller capsule size and is crafted to enhance the user experience through efficient nutrient absorption—while preserving or boosting functional effectiveness.
New Proprietary Bottle Design
Alongside the product upgrade, EUDA is rolling out a new proprietary EUDA Helixé bottle design that reflects the supplement’s premium status while improving product protection, shelf appeal, and brand recognition.
New Zealand Halal Certification and Global Market Expansion
EUDA Helixé 2.0 has received New Zealand Halal certification, allowing for wider international distribution and official access to Muslim markets in Southeast Asia, the Middle East, and other global regions.
Positioning EUDA Helixé for Global Growth
The January 2026 launch of EUDA Helixé 2.0 underscores EUDA Health’s dedication to continuous innovation, scientific progress, and scalable global wellness solutions. Equipped with stronger formulation, advanced delivery technology, upgraded packaging, and wider market access, EUDA Helixé 2.0 is positioned as a key product in EUDA’s expanding health and longevity ecosystem.
Mr Alfred Lim, CEO of EUDA, commented:
“This represents a key milestone in EUDA’s product development. With EUDA Helixé 2.0, we’re fortifying our core formulation, upgrading delivery technology, and expanding global market access via Halal certification. These improvements reflect our commitment to science-driven innovation and position EUDA Helixé as a premium longevity supplement—aligned with EUDA’s broader strategy to scale high-quality wellness solutions worldwide.”
About EUDA Health Holdings Limited
EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-headquartered leading non-invasive healthcare provider in Asia, focusing on Singapore, Malaysia, and China. The Company aims to be a market leader in non-invasive and preventive healthcare, with a strategic emphasis on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people in the region—where more than 30% of the population is aging rapidly. By providing innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the shift in regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also operates a Singapore-based property management business.
Forward-Looking Statements
This document may include forward-looking statements about risks and uncertainties. Such statements typically use forward-looking terms like “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose”—and variations or similar expressions (including negative versions). These forward-looking statements are not guarantees of future performance, conditions, or results. They involve numerous known and unknown risks, uncertainties, assumptions, and other key factors—many beyond EUDA’s control—that could cause actual results or outcomes to differ significantly from those discussed in the forward-looking statements. You should not place undue reliance on forward-looking statements, which apply only as of the document’s publication date. The Company does not have an obligation to update or revise any forward-looking statements, whether due to new information, future events, or other reasons—except as required by law.
Contact
Christensen Advisory
Linda Bergkamp
Phone: +1-480-614-3004
E-mail:
